Oppenheimer Adjusts Eloxx Pharmaceuticals' Price Target to $55 From $50, Keeps Outperform Rating
Oppenheimer Adjusts Eloxx Pharmaceuticals' Price Target to $55 From $50, Keeps Outperform Rating
奧本海默將Eloxx Pharmicals的目標股價從50美元調整至55美元，維持表現跑贏大盤的評級
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊